People: Galectin Therapeutics Inc (GALT.W)

Summary

Name	Age	Since	Current Position
James Czirr	57	2010	Executive Chairman of the Board
Peter Traber	55	2011	President, Chief Executive Officer, Director
Rod Martin	41	2010	Independent Vice Chairman of the Board
Harold Shlevin	62	2012	Chief Operating Officer
Eliezer Zomer	65	2000	Executive Vice President - Manufacturing and Product Development
Anatole Klyosov	64	2000	Chief Scientist
Gilbert Amelio	70	2009	Independent Director
Kevin Freeman	50	2011	Independent Director
Arthur Greenberg	64	2009	Independent Director
John Mauldin	62	2011	Independent Director
Steven Prelack	53	2003	Independent Director
H. Paul Pressler	80	2011	Independent Director
Jerald Rome	76	2004	Independent Director
Marc Rubin	58	2011	Independent Director

» Insider Trading

Biographies

Name	Description
James Czirr	Mr. James C. Czirr serves as Executive Chairman of the Board of Galectin Therapeutics Inc. He served as Chairman of the Board since February 2009 and Executive Chairman since February 2010, is a co-founder of 10X Fund, L.P. and is a managing member of 10X Capital Management LLC, the general partner of 10X Fund, L.P. Mr. Czirr was a co-founder of Galectin Therapeutics in July 2000. Mr. Czirr was instrumental in the early stage development of Safe Science Inc., a developer of anti-cancer drugs, served from 2005 to 2008 as Chief Executive Officer of Minerva Biotechnologies Corporation, a developer of nano particle bio chips to determine the cause of solid tumors, and was a consultant to Metalline Mining Company Inc., now known as Silver Bull Resources, Inc., (NYSE Amex: SVBL), a mineral exploration company seeking to become a low cost producer of zinc. Mr. Czirr received a B.B.A. degree from the University of Michigan.
Peter Traber	Dr. Peter G. Traber, M.D., serves as President, Chief Executive Officer, Director of Galectin Therapeutics Inc. Dr. Traber is a director since February 2009, was appointed President and Chief Executive Officer effective March 17, 2011, and has served as Chief Medical Officer since June 2010. Dr. Traber is President Emeritus, and from 2003 to 2008 was Chief Executive Officer, of Baylor College of Medicine. From 2000 to 2003 he was Senior Vice President Clinical Development and Regulatory Affairs and Chief Medical Officer of GlaxoSmithKline plc. He has also served as Chief Executive Officer of the University of Pennsylvania Health System, as well as Chair of the Department of Internal Medicine and Chief of Gastroenterology for the University of Pennsylvania School of Medicine. Dr. Traber received his M.D. from Wayne State School of Medicine and a B.S. in chemical engineering from the University of Michigan.
Rod Martin	Mr. Rod D. Martin, J.D., serves as an Independent Vice Chairman of the Board of Galectin Therapeutics Inc., since February 11, 2010. Mr. Martin is a co-founder of 10X Fund, L.P. and is a managing member of 10X Capital Management LLC, the general partner of 10X Fund, L.P. Mr. Martin served as a senior advisor to PayPal, Inc. founder Peter Thiel, during the company’s startup phase, its initial public offering and its subsequent acquisition by eBay Inc.; and afterward, served at Clarium Capital, Thiel’s global macro hedge fund which had more than $7.8 billion under management. Mr. Martin is founder and chairman of the board of Advanced Search Laboratories, Inc., and also serves as a director of Proxomo Software. He previously served as Director of Policy Planning & Research for former Arkansas Governor Mike Huckabee. He is a widely noted author and speaker, and leads several non-profit organizations. Mr. Martin holds a J.D. from Baylor Law School, a B.A. from the University of Arkansas, and was a Sturgis Fellow at Cambridge University in Great Britain.
Harold Shlevin	Dr. Harold H. Shlevin, Ph.D., has been appointed as Chief Operating Officer of Galectin Therapeutics Inc., effective October 1, 2012. Dr. Shlevin most recently led Georgia Institute of Technology’s Advanced Technology Development Center (ATDC) as Principle and Manager of bioscience commercialization efforts, where he served as a catalyst for new bioscience startup companies. His leadership roles have included: President and CEO of Solvay Pharmaceuticals, where he oversaw the launch of the first topical testosterone gel product in the US; co-founder of CIBA Vision Ophthalmics, a specialty ophthalmic drug company, where he headed efforts to the approval of the first non-steroidal agent for treatment of ocular inflammation and several other drug products; founder, President & CEO of Tikvah Therapeutics, a company focused on clinical development of therapeutics for treatment of neurological diseases; and VP and Head of Operations & Commercial Development for Altea Therapeutics Corporation, a clinical-stage drug delivery company with platform technology applicable to the transdermal delivery of biologics. Dr. Shlevin earned his BA from Boston University and MS and PhD in physiology from the University of Rochester Medical School. He completed post-doctoral training in pharmacology at Mayo Clinic where he subsequently served as Assistant Professor of Pharmacology & Physiology. He is a member of scientific and business societies including IEEE, Licensing Executives Society, Am. Physiological Society, Am. Society of Pharmacology & Experimental Therapeutics, and is an inventor on several issued and pending patents. Dr. Shlevin currently serves on the Board of Directors of Cardiome Pharma Corp. (NASDAQ:CRME) and NeurOp, Inc. and as an advisor to Clearside Biomedical, Inc.
Eliezer Zomer	Dr. Eliezer Zomer, Ph.D., serves as Executive Vice President of Manufacturing and Product Development of Galectin Therapeutics Inc. Prior to joining company, Dr. Zomer had been the founder of Alicon Biological Control, where he served from November 2000 to July 2002. From December 1998 to July 2000, Dr. Zomer served as Vice President of product development at SafeScience, Inc. and Vice President of Research and Development at Charm Sciences, Inc. from June 1987 to November 1998. Dr. Zomer received a B. Sc. degree in industrial microbiology from the University of Tel Aviv in 1972, a Ph.D. in biochemistry from the University of Massachusetts in 1978, and undertook a post-doctoral study at the National Institute of Health.
Anatole Klyosov	Dr. Anatole Klyosov, Ph.D., D.Sc., serves as Chief Scientist of Galectin Therapeutics Inc., since 2000. He is a co-inventor of patented technology and a founder of Pro-Pharmaceuticals. Dr. Klyosov was vice president, research and development for Kadant Composites, Inc., a subsidiary of Kadant, Inc. (KAI-NYSE), where he directed, since 1996, a laboratory performing work in biochemistry, microbiology and polymer engineering. From 1990 to 1998, Dr. Klyosov was visiting professor of biochemistry, Center for Biochemical and Biophysical Sciences, Harvard Medical School, and from 1981 to 1990 he was professor and head of the Carbohydrates Research Laboratory at the A.N. Bach Institute of Biochemistry, USSR Academy of Sciences. Dr. Klyosov was elected as a member of the World Academy of Art and Sciences and is the recipient of distinguished awards including the USSR National Award in Science and Technology. He has published more than 250 peer- reviewed articles in scientific journals, authored books on enzymes, carbohydrates, and biotechnology, edited two books: Carbohydrates in Drug Design and Galectins, and holds more than 20 patents. Dr. Klyosov earned his Ph.D. and D.Sc. degrees in physical chemistry, and an M.S. degree in enzyme kinetics, from Moscow State University.
Gilbert Amelio	Dr. Gilbert F. Amelio, Ph.D., serves as an Independent Director of Galectin Therapeutics Inc., since February 12, 2009. He began his career at Bell Labs, is Senior Partner of Sienna Ventures (a privately-held venture capital firm in Sausalito, California) and has acted in this capacity since April 2001. Dr. Amelio was Chairman and Chief Executive Officer of Jazz Technologies, Inc. (a wholly owned subsidiary of Tower Semiconductor Ltd., an independent specialty wafer foundry) from August 2005 until his retirement in September 2008 (when he was named Chairman Emeritus). Dr. Amelio was Chairman and Chief Executive Officer of Beneventure Capital, LLC (a full-service venture capital firm in San Francisco, California) from 1999 to 2005 and was Principal of Aircraft Ventures, LLC (a consulting firm in Newport Beach, California) from April 1997 to December 2004. In 2008, Acquicor Management LLC (a former shareholder of Jazz Technologies, Inc.), where Dr. Amelio has served as the sole managing member since 2005, declared bankruptcy. Dr. Amelio was elected a Director of AT&T in February 2001 and had previously served as an Advisory Director of AT&T (then known as SBC Communications Inc.) from April 1997 to February 2001. He served as a Director of Pacific Telesis Group from 1995 until the company was acquired by AT&T in 1997.
Kevin Freeman	Mr. Kevin D. Freeman serves as an Independent Director of Galectin Therapeuctics Inc. He is a Certified Financial Adviser and registered investment adviser, is Chief Executive Officer of Freeman Global Investment Counsel, an investment advisory firm founded in 2004 operating under Cross Consulting Services LLC, where he serves as President. He is also Chief Investment Officer of Capitalist Publishing Co., Inc. Formerly he was Chairman of Separate Account Services, Inc. and held several offices at Franklin Templeton Investment Services. He holds a B.S. in business administration from University of Tulsa, Tulsa, Oklahoma.
Arthur Greenberg	Mr. Arthur R. Greenberg serves as an Independent Director of Galectin Therapeutics Inc., since August 2009. He has 37 years in the semiconductor equipment and materials industries. He is the President and Founder of Prism Technologies, Inc. which provides professional sales and marketing services and business development consulting services. Mr. Greenberg is a member of the board of UV Tech Systems, a designer and manufacturer of equipment used to fabricate semiconductor devices. Previously, he was the first President of SEMI, North America, a semiconductor equipment and materials industry trade association representing the interests, including public policy, of more than 2000 members doing business in North America. Mr. Greenberg received his B.S. degree in business administration from Henderson State University.
John Mauldin	Mr. John Mauldin serves as an Independent Director of Galectin Therapeuctics Inc. Mr. Mauldin is President of Millennium Wave Advisors LLC, an investment advisory firm, and a registered representative of Millennium Wave Securities, LLC, a FINRA registered broker-dealer. Previously he was Chief Executive Officer of the American Bureau of Economic Research. He has many publications on investments and financial topics, including a New York Times bestseller and articles in the Financial Times and The Daily Reckoning, and is a frequent guest on CNBC, Yahoo Tech Ticker and Bloomberg TV. He holds a B.A. from Rice University and a M.Div. from Southwestern Baptist Theological Seminary.
Steven Prelack	Mr. Steven Prelack serves as an Independent Director of Galectin Therapeutics Inc. He has served a director since April 2003, has been since July 2010 Senior Vice President of Operations and Chief Financial Officer of VetCor which owns and operates 49 veterinary hospitals. Previously, from 2001, he was Senior Vice President, Chief Financial Officer and Treasurer of VelQuest Corporation, a provider of automated compliance software solutions for the pharmaceutical industry. In this capacity, Mr. Prelack oversees sales, business development, operations and finance. Mr. Prelack is a director of Codeco Corporation, a designer and manufacturer of custom resisters and switches, and is a member of the Strategic Advisory Board of BioVex, a Biotechnology company focused on cancer. Mr. Prelack served as Director and Audit Committee Chair for BioVex from 2007 through 2009. Mr. Prelack, a Certified Public Accountant, received a B.B.A. degree from the University of Massachusetts at Amherst in 1979.
H. Paul Pressler	Judge (Retd.) H. Paul Pressler serves as an Independent Director of Galectin Therapeuctics Inc. Mr. Pressler has been a partner in the law firm of Woodfill & Pressler since 1995, has served as a director of Revelation, Inc., and was in private mediation practice. A retired justice of the Texas Court of Appeals, Judge Pressler was appointed Justice of the Texas Court of Appeals in 1978, serving until 1992. Judge Pressler also served as District Judge from 1970 to 1978. From 1958 to 1970, he was associated with the law firm of Vinson & Elkins. Judge Pressler has been a director of Salem Communications Corporation since March 2002, and is also a board member of the Free Market Foundation and KHCB Network, a non-profit corporation which owns Christian radio stations in Texas and Louisiana, and a board member of National Religious Broadcasters. He has been an active leader in the Southern Baptist Convention.
Jerald Rome	Mr. Jerald K. Rome serves as an Independent Director of Galectin Therapeutics Inc. He has been a director since March 2004, has been a private investor since 1996. Mr. Rome founded Amberline Pharmaceutical Care Corp., a marketer of non-prescription pharmaceuticals, in 1993 and served as its President from 1993 to 1996. From 1980 to 1990, he served as Chairman, President and Chief Executive Officer of Moore Medical Corp., a national distributor of branded pharmaceuticals and manufacturer and distributor of generic pharmaceuticals and was previously Executive Vice President of the H.L. Moore Drug Exchange, a division of Parkway Distributors and predecessor of Moore Medical Corp. Mr. Rome received a B.S. degree in pharmaceutical sciences from the University of Connecticut.
Marc Rubin	Dr. Marc Rubin, M.D., serves as Independent Director of Galectin Therapeutics Inc., since October 11, 2011. Dr. Rubin has served as President and Chief Executive of Titan Pharmaceuticals, Inc. (OTC: TTNP) since October 2007, and has been a Director since November 2007. Dr. Rubin previously served as Head of Global Research and Development for Bayer Schering Pharma, as well as a member of the Executive Committee of Bayer Healthcare and the Board of Management of Bayer Schering Pharma. Prior to the merger of Bayer Pharmaceuticals and Schering AG in June 2006, Dr. Rubin was a member of the Executive Board of Schering AG, as well as Chairman of Schering Berlin Inc. and President of Berlex Pharmaceuticals, a division of Schering AG. From 1990 until August 2003, Dr. Rubin was employed by GlaxoSmithKline where he held positions of responsibility in global clinical and commercial development overseeing programs in the United States, Europe, Asia and Latin America. From 2001 through 2003, he was Senior Vice President of Global Clinical Pharmacology & Discovery Medicine. Dr. Rubin holds an M.D. from Cornell University Medical College, completed internship and residency in Internal Medicine at the Johns Hopkins Hospital, and fellowships in Medical Oncology and Infectious Diseases at the National Institutes of Health. Dr. Rubin is a member of the Board of Directors of Curis Inc. (Nasdaq: CRIS) and formerly served on the Board of Directors of Medarex, Inc., now a subsidiary of Bristol-Myers Squibb Company.

Basic Compensation

Name	Fiscal Year Total
James Czirr	3,168,030
Peter Traber	5,733,850
Rod Martin	--
Harold Shlevin	--
Eliezer Zomer	134,471
Anatole Klyosov	203,694
Gilbert Amelio	--
Kevin Freeman	--
Arthur Greenberg	--
John Mauldin	--
Steven Prelack	--
H. Paul Pressler	--
Jerald Rome	--
Marc Rubin	--

As Of 30 Dec 2011

Options Compensation

Name	Options	Value
James Czirr	0	0
Peter Traber	0	0
Rod Martin	0	0
Harold Shlevin	0	0
Eliezer Zomer	620,000	86,250
Anatole Klyosov	0	0
Gilbert Amelio	0	0
Kevin Freeman	0	0
Arthur Greenberg	0	0
John Mauldin	0	0
Steven Prelack	0	0
H. Paul Pressler	0	0
Jerald Rome	0	0
Marc Rubin	0	0

Insider Trading

Name	Shares Traded	Price
SHLEVIN HAROLD H	46,586	$4.98
SHLEVIN HAROLD H	100,000	$2.32
PRELACK STEVEN	631	$4.22
PRELACK STEVEN	1,167	$2.28
ROME JERALD K	2,500	$2.28
TRABER PETER G	2,500	$2.11
TRABER PETER G	2,500	$2.00
TRABER PETER G	5,000	$2.07
GREENBERG ARTHUR R	5,000	$1.84
AMELIO GILBERT F	7,500	$2.10
PRELACK STEVEN	2,400	$2.14
MARTIN ROD D	5,000	$2.44
MCGAULEY THOMAS A	10,000	$2.35
CZIRR JAMES C	10,000	$2.25
MAULDIN JOHN F	1,100	$3.08
PRESSLER HERMAN PAUL III	5,000	$3.10
MAULDIN JOHN F	3,847	$2.94
GREENBERG ARTHUR R	3,000	$2.84
RUBIN MARC	20,000	$0.96
MARTIN ROD D	2,410,000	$0.50
CZIRR JAMES C	206,724	$0.92
CZIRR JAMES C	6,000	$1.00
CZIRR JAMES C	2,410,000	$0.50
MARTIN ROD D	206,724	$0.92
10X FUND L P	206,724	$0.92

» Full list on Insider Trading

People: Galectin Therapeutics Inc (GALT.W)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: